F1324 acetate

CAS No. ——

F1324 acetate( —— )

Catalog No. M30205 CAS No. ——

F1324 acetate is an efficient, high-affinity b-cell lymphoma inhibitor with IC50 of 1 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    F1324 acetate
  • Note
    Research use only, not for human use.
  • Brief Description
    F1324 acetate is an efficient, high-affinity b-cell lymphoma inhibitor with IC50 of 1 nM.
  • Description
    F1324 acetate is an efficient, high-affinity b-cell lymphoma inhibitor with IC50 of 1 nM.(In Vitro):F1324 acetate binds to BCL6(5-129) with KD and IC50 values of 0.57 nM and 1 nM according to the results of an SPR analysis and cell-free ELISA assay, respectively. F1324 acetate binds BCL6 not only in cell-free but also cellbased conditions.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    IC50: 1 nM (BCL6)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    1825.09
  • Molecular Formula
    C85H125N21O22S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:Ac-{Leu}{Trp}{Tyr}{Thr}{Asp}{Ile}{Arg}{Met}{Ser}{Trp}{Arg}{Val}{Pro}-OH

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Sakamoto K, et al. Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship. Biochem Biophys Res Commun. 2017 Jan 8;482(2):310-316.
molnova catalog
related products
  • 3-Amino-5-methylisox...

    Pharmaceutical intermediates. Used in the production of sulfonamide drugs.

  • ACBI3

    ACBI3 (compound 7), a pan-KRAS degrader, effectively accomplishes the in vivo degradation of oncogenic KRAS .

  • RS-127445

    RS-127445 is a selective 5-HT2B receptor antagonist with pKi of 9.5 and pIC50 of 10.4, exhibits >1000-fold selectivity against other 5-HT receptors.